Phibro Animal Health Corporation Reports Third Quarter Results, Updates Financial Guidance
Phibro Animal Health reported strong financial results for the third quarter, with net sales increasing by 7% and adjusted EBITDA up by 9%. The company affirmed its fiscal year 2024 guidance, including net sales of $980 million to $1.020 billion and adjusted diluted EPS of $1.04 to $1.16. Phibro also updated its guidance for net income and diluted EPS due to recent developments.
Net sales increased by 7% to $263.2 million for the three months ended March 31, 2024.
Adjusted EBITDA rose by 9% to $29.7 million for the same period.
Phibro affirmed its fiscal year 2024 guidance, including net sales of $980 million to $1.020 billion.
Adjusted diluted EPS increased by 9% to $0.31 for the quarter.
Net income decreased from $10.0 million to $8.4 million for the three months ended March 31, 2024.
Diluted earnings per share declined from $0.25 to $0.21 for the same period.
Updated guidance shows a decline in net income from $7 million to $12 million and diluted EPS from $0.17 to $0.30 for fiscal year 2024.
Highlights for the three months ended March 31, 2024 (compared to the three months ended March 31, 2023)
-
Net sales of
, an increase of$263.2 million , or$17.6 million 7% -
Net income of
, a decrease of$8.4 million $1.6 million -
Diluted earnings per share of
, a decrease of$0.21 $0.04 -
Adjusted EBITDA of
, an increase of$29.7 million , or$2.3 million 9% -
Adjusted net income of
, an increase of$12.7 million , or$1.1 million 9% -
Adjusted diluted EPS of
, an increase of$0.31 , or$0.02 9%
We affirm our previously issued fiscal year 2024 guidance for the following measures:
-
Net sales of
to$980 million $1.02 0 billion -
Adjusted EBITDA of
to$106 million $112 million -
Adjusted net income of
to$42 million $47 million -
Adjusted diluted EPS of
to$1.04 $1.16 -
Adjusted effective tax rate of
28% to30%
We have updated our fiscal year 2024 guidance for the following measures:
-
Net income of
to$7 million $12 million -
Diluted EPS of
to$0.17 $0.30
Our guidance is on a standalone basis without giving effect to the acquisition of Zoetis’ Medicated Feed Additive portfolio.
COMMENTARY
“I am extraordinarily proud of our third quarter performance. Our Animal Health segment delivered double digit top line growth, led by
Jack continued, “This growth was achieved while at the same time our team was heavily involved in the process that led to our announcement last week of our signed agreement to purchase Zoetis’ Medicated Feed Additive portfolio and certain water-soluble products. We are excited to bring the people and products included in the transaction to Phibro and we are very confident that we have the operational strength and focus to not only have a smooth transition but to maximize the opportunity related to this portfolio of products which will enhance, expand and diversify Phibro’s species and product offerings. We anticipate this transaction will lead to strong earnings accretion and debt paydown and will also serve as the engine that will continue to power our investments in the faster growing vaccines, nutritional specialties, and companion animal product segments.”
QUARTERLY RESULTS
Net sales
Net sales of
Animal Health
Net sales of
Mineral Nutrition
Net sales of
Performance Products
Net sales of
Gross profit
Gross profit of
Animal Health gross profit increased
Selling, general and administrative expenses
Selling, general and administrative expenses (“SG&A”) of
Animal Health SG&A increased
Interest expense, net
Interest expense, net of
Foreign currency losses (gains), net
Foreign currency losses, net for the three months ended March 31, 2024, were
Provision for income taxes
The provision for income taxes was
Net income
Net income of
Adjusted EBITDA
Adjusted EBITDA of
Adjusted provision for income taxes
The adjusted provision for income taxes was
Adjusted net income
Adjusted net income of
Adjusted diluted earnings per share
Adjusted diluted earnings per share was
BALANCE SHEET AND CASH FLOWS
-
Free cash flow was
for the twelve months ended March 31, 2024$40.3 million -
4.4x gross leverage ratio as of March 31, 2024
-
total debt$487.0 million -
Adjusted EBITDA for the twelve months ended March 31, 2024$110.1 million
-
-
Cash and short-term investments of
as of March 31, 2024$98.7 million
FISCAL YEAR 2024 FINANCIAL GUIDANCE
Our affirmed or updated fiscal year 2024 financial guidance is as shown in the table below. Comparisons are to the prior fiscal year and year-over-year percentages are calculated using the midpoint of the guidance ranges.
-
Net sales of
to$980 million , growth of$1.02 0 billion2% , affirmed -
Net income of
to$7 million , a decline of$12 million 70% , updated -
Diluted EPS of
to$0.17 , a decline of$0.30 70% , updated -
Adjusted EBITDA of
to$106 million , a decline of$112 million 3% , affirmed -
Adjusted net income of
to$42 million , a decline of$47 million 9% , affirmed -
Adjusted diluted EPS of
to$1.04 , a decline of$1.16 9% , affirmed -
Adjusted effective tax rate of
28% to30% , affirmed
The updated guidance reflects recent developments, including additional acquisition-related expenses, a gain from insurance proceeds and the related effects on the provision for income taxes. Each of these items are reflected in our GAAP guidance but are excluded from adjusted measures.
Our guidance is on a standalone basis without giving effect to the acquisition of Zoetis’ Medicated Feed Additive portfolio.
WEBCAST & CONFERENCE CALL DETAILS
Phibro Animal Health Corporation will host a webcast and conference call during which the Company will review its financial results and respond to questions.
Date: |
Thursday, May 9, 2024 |
|
Time: |
9:00 AM Eastern |
|
Location: |
||
|
+1 (888) 330-2022 |
|
International Toll: |
+1 (365) 977-0051 |
|
Conference ID: |
3927884 |
NOTE: To join this conference call, all participants will be required to provide the Conference ID number.
A replay of the webcast will be archived and made available on Phibro’s website.
DISCLOSURE NOTICES
Forward-Looking Statements: This communication contains forward-looking statements that are subject to risks and uncertainties. All statements other than statements of historical or current fact included in this report are forward-looking statements. Forward-looking statements discuss our current expectations and projections relating to our financial condition, results of operations, plans, objectives, future performance and business. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “aim,” “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “outlook,” “potential,” “project,” “projection,” “plan,” “intend,” “seek,” “may,” “could,” “would,” “will,” “should,” “can,” “can have,” “likely,” the negatives thereof and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. These statements are not guarantees of future performance or actions. If one or more of these risks or uncertainties materialize, or if management’s underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Phibro expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Quarterly Report on Form 10-Q and Annual Report on Form 10-K, including in the sections thereof captioned “Forward-Looking Statements” and “Risk Factors.” These filings and subsequent filings are available online at www.sec.gov, www.pahc.com, or on request from Phibro.
Non-GAAP Financial Information: We use non-GAAP financial measures, such as adjusted EBITDA, adjusted net income, adjusted diluted EPS and free cash flow to assess and analyze our operational results and trends and to make financial and operational decisions. Management uses adjusted EBITDA as its primary operating measure. We report adjusted net income to portray the results of our operations prior to considering certain income statement elements. We believe these non-GAAP financial measures are also useful to investors because they provide greater transparency regarding our operating performance. The non-GAAP financial measures included in this communication should not be considered alternatives to measurements required by GAAP, such as net income, operating income and earnings per share, and should not be considered measures of liquidity. These non-GAAP financial measures are unlikely to be comparable with non-GAAP information provided by other companies. Reconciliation of non-GAAP financial measures and GAAP financial measures are included in the tables accompanying this communication and/or our Quarterly Report on Form 10-Q and Annual Report on Form 10-K.
We are not providing a reconciliation of forward-looking guidance of non-GAAP financial measures to the most directly comparable GAAP financial measures because of the uncertainty regarding, and the potential variability of, certain of the items required for a reconciliation; accordingly, a reconciliation of the non-GAAP financial measure to the corresponding GAAP financial measure is not available without unreasonable effort.
Internet Posting of Information: We routinely post information that may be important to investors in the “Investors” section of our website at www.pahc.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Phibro Animal Health Corporation |
||||||||||||||||||||||||||||||
Consolidated Results of Operations |
||||||||||||||||||||||||||||||
|
|
Three Months |
|
Nine Months |
||||||||||||||||||||||||||
For the Periods Ended March 31 |
|
2024 |
|
2023 |
|
Change |
|
2024 |
|
2023 |
|
Change |
||||||||||||||||||
|
|
(in millions, except per share amounts and percentages) |
||||||||||||||||||||||||||||
Net sales |
|
$ |
263.2 |
|
$ |
245.7 |
|
$ |
17.6 |
|
7 |
% |
$ |
744.5 |
|
$ |
722.8 |
|
$ |
21.7 |
|
3 |
% |
|||||||
Cost of goods sold |
|
|
183.6 |
|
|
170.1 |
|
|
13.5 |
|
8 |
% |
|
518.6 |
|
|
501.3 |
|
|
17.3 |
|
3 |
% |
|||||||
Gross profit |
|
|
79.6 |
|
|
75.5 |
|
|
4.1 |
|
5 |
% |
|
225.9 |
|
|
221.6 |
|
|
4.4 |
|
2 |
% |
|||||||
Selling, general and administrative |
|
|
59.7 |
|
|
57.0 |
|
|
2.7 |
|
5 |
% |
|
191.0 |
|
|
173.5 |
|
|
17.6 |
|
10 |
% |
|||||||
Operating income |
|
|
19.9 |
|
|
18.6 |
|
|
1.4 |
|
7 |
% |
|
34.9 |
|
|
48.1 |
|
|
(13.2 |
) |
* |
% |
|||||||
Interest expense, net |
|
|
4.6 |
|
|
3.9 |
|
|
0.7 |
|
18 |
% |
|
13.8 |
|
|
10.8 |
|
|
3.0 |
|
27 |
% |
|||||||
Foreign currency losses (gains), net |
|
|
2.4 |
|
|
(0.4 |
) |
|
2.8 |
|
* |
|
16.6 |
|
|
4.6 |
|
|
12.0 |
|
* |
|||||||||
Income before income taxes |
|
|
12.9 |
|
|
15.1 |
|
|
(2.2 |
) |
(14 |
)% |
|
4.5 |
|
|
32.6 |
|
|
(28.1 |
) |
* |
||||||||
Provision for income taxes |
|
|
4.5 |
|
|
5.1 |
|
|
(0.5 |
) |
(11 |
)% |
|
2.8 |
|
|
11.5 |
|
|
(8.7 |
) |
* |
||||||||
Net income |
|
$ |
8.4 |
|
$ |
10.0 |
|
$ |
(1.6 |
) |
(16 |
)% |
$ |
1.7 |
|
$ |
21.1 |
|
$ |
(19.4 |
) |
* |
||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
Net income per share |
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
basic |
|
$ |
0.21 |
|
$ |
0.25 |
|
$ |
(0.04 |
) |
(16 |
)% |
$ |
0.04 |
|
$ |
0.52 |
|
$ |
(0.48 |
) |
* |
||||||||
diluted |
|
$ |
0.21 |
|
$ |
0.25 |
|
$ |
(0.04 |
) |
(16 |
)% |
$ |
0.04 |
|
$ |
0.52 |
|
$ |
(0.48 |
) |
* |
||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
Weighted average common shares outstanding |
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
basic |
|
|
40.5 |
|
|
40.5 |
|
|
|
|
40.5 |
|
|
40.5 |
|
|
|
|||||||||||||
diluted |
|
|
40.5 |
|
|
40.5 |
|
|
|
|
40.5 |
|
|
40.5 |
|
|
|
|||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
Ratio to net sales |
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
Gross profit |
|
|
30.2 |
% |
|
30.7 |
% |
|
|
|
30.3 |
% |
|
30.7 |
% |
|
|
|||||||||||||
Selling, general and administrative |
|
|
22.7 |
% |
|
23.2 |
% |
|
|
|
25.7 |
% |
|
24.0 |
% |
|
|
|||||||||||||
Operating income |
|
|
7.6 |
% |
|
7.6 |
% |
|
|
|
4.7 |
% |
|
6.7 |
% |
|
|
|||||||||||||
Income before income taxes |
|
|
4.9 |
% |
|
6.1 |
% |
|
|
|
0.6 |
% |
|
4.5 |
% |
|
|
|||||||||||||
Net income |
|
|
3.2 |
% |
|
4.1 |
% |
|
|
|
0.2 |
% |
|
2.9 |
% |
|
|
|||||||||||||
Effective tax rate |
|
|
35.0 |
% |
|
33.5 |
% |
|
|
|
63.1 |
% |
|
35.3 |
% |
|
|
Amounts and percentages may reflect rounding adjustments. |
* Calculation not meaningful |
Phibro Animal Health Corporation |
||||||||||||||||||||||||||||||
Segment Net Sales and Adjusted EBITDA |
||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
|
|
Three Months |
|
Nine Months |
||||||||||||||||||||||||||
For the Periods Ended March 31 |
|
2024 |
|
2023 |
|
Change |
|
2024 |
|
2023 |
|
Change |
||||||||||||||||||
|
|
(in millions, except percentages) |
||||||||||||||||||||||||||||
Net Sales |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
MFAs and other |
|
$ |
108.2 |
|
$ |
93.2 |
|
$ |
15.0 |
|
16 |
% |
$ |
304.3 |
|
$ |
283.2 |
|
$ |
21.1 |
|
|
7 |
% |
||||||
Nutritional specialties |
|
|
40.2 |
|
|
45.0 |
|
|
(4.8 |
) |
(11 |
)% |
|
121.8 |
|
|
127.9 |
|
|
(6.1 |
) |
|
(5 |
)% |
||||||
Vaccines |
|
|
32.9 |
|
|
26.2 |
|
|
6.7 |
|
26 |
% |
|
88.9 |
|
|
72.0 |
|
|
16.9 |
|
|
23 |
% |
||||||
Animal Health |
|
|
181.3 |
|
|
164.4 |
|
|
16.9 |
|
10 |
% |
|
515.0 |
|
|
483.1 |
|
|
31.9 |
|
|
7 |
% |
||||||
Mineral Nutrition |
|
|
64.2 |
|
|
62.9 |
|
|
1.3 |
|
2 |
% |
|
181.6 |
|
|
184.2 |
|
|
(2.6 |
) |
|
(1 |
)% |
||||||
Performance Products |
|
|
17.7 |
|
|
18.3 |
|
|
(0.7 |
) |
(4 |
)% |
|
47.9 |
|
|
55.5 |
|
|
(7.6 |
) |
|
(14 |
)% |
||||||
Total |
|
$ |
263.2 |
|
$ |
245.7 |
|
$ |
17.6 |
|
7 |
% |
$ |
744.5 |
|
$ |
722.8 |
|
$ |
21.7 |
|
|
3 |
% |
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Adjusted EBITDA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Animal Health |
|
$ |
36.5 |
|
$ |
34.2 |
|
$ |
2.3 |
|
7 |
% |
$ |
104.3 |
|
$ |
98.2 |
|
$ |
6.1 |
|
|
6 |
% |
||||||
Mineral Nutrition |
|
|
4.7 |
|
|
3.9 |
|
|
0.8 |
|
21 |
% |
|
11.1 |
|
|
13.6 |
|
|
(2.5 |
) |
|
(18 |
)% |
||||||
Performance Products |
|
|
2.4 |
|
|
2.4 |
|
|
(0.0 |
) |
(2 |
)% |
|
4.6 |
|
|
7.1 |
|
|
(2.5 |
) |
|
(35 |
)% |
||||||
Corporate |
|
|
(13.9 |
) |
|
(13.1 |
) |
|
(0.7 |
) |
6 |
% |
|
(42.2 |
) |
|
(38.5 |
) |
|
(3.7 |
) |
|
10 |
% |
||||||
Total |
|
$ |
29.7 |
|
$ |
27.4 |
|
$ |
2.3 |
|
9 |
% |
$ |
77.8 |
|
$ |
80.4 |
|
$ |
(2.6 |
) |
|
(3 |
)% |
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Ratio to segment net sales |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Animal Health |
|
|
20.1 |
% |
|
20.8 |
% |
|
|
|
|
20.3 |
% |
|
20.3 |
% |
|
|
|
|
||||||||||
Mineral Nutrition |
|
|
7.3 |
% |
|
6.1 |
% |
|
|
|
|
6.1 |
% |
|
7.4 |
% |
|
|
|
|
||||||||||
Performance Products |
|
|
13.4 |
% |
|
13.2 |
% |
|
|
|
|
9.6 |
% |
|
12.7 |
% |
|
|
|
|
||||||||||
Corporate (1) |
|
|
(5.3 |
)% |
|
(5.3 |
)% |
|
|
|
|
(5.7 |
)% |
|
(5.3 |
)% |
|
|
|
|
||||||||||
Total (1) |
|
|
11.3 |
% |
|
11.1 |
% |
|
|
|
|
10.5 |
% |
|
11.1 |
% |
|
|
|
|
||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Reconciliation of GAAP Net Income to Adjusted EBITDA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Net income |
|
$ |
8.4 |
|
$ |
10.0 |
|
$ |
(1.6 |
) |
(16 |
)% |
$ |
1.7 |
|
$ |
21.1 |
|
$ |
(19.4 |
) |
|
* |
|||||||
Interest expense, net |
|
|
4.6 |
|
|
3.9 |
|
|
0.7 |
|
18 |
% |
|
13.8 |
|
|
10.8 |
|
|
3.0 |
|
|
27 |
% |
||||||
Provision for income taxes |
|
|
4.5 |
|
|
5.1 |
|
|
(0.5 |
) |
(11 |
)% |
|
2.8 |
|
|
11.5 |
|
|
(8.7 |
) |
|
* |
|||||||
Depreciation and amortization |
|
|
9.2 |
|
|
8.5 |
|
|
0.7 |
|
8 |
% |
|
27.0 |
|
|
25.4 |
|
|
1.5 |
|
|
6 |
% |
||||||
EBITDA |
|
|
26.7 |
|
|
27.5 |
|
|
(0.8 |
) |
(3 |
)% |
|
45.3 |
|
|
68.9 |
|
|
(23.6 |
) |
|
(34 |
)% |
||||||
Acquisition-related cost of goods sold |
|
|
0.2 |
|
|
— |
|
|
0.2 |
|
* |
|
0.5 |
|
|
— |
|
|
0.5 |
|
|
* |
||||||||
Acquisition-related other |
|
|
0.5 |
|
|
— |
|
|
0.5 |
|
* |
|
0.5 |
|
|
— |
|
|
0.5 |
|
|
* |
||||||||
Pension settlement cost |
|
|
— |
|
|
— |
|
|
— |
|
* |
|
10.7 |
|
|
— |
|
|
10.7 |
|
|
* |
||||||||
Insurance proceeds |
|
|
(0.3 |
) |
|
— |
|
|
(0.3 |
) |
* |
|
(0.3 |
) |
|
— |
|
|
(0.3 |
) |
|
* |
||||||||
|
|
|
— |
|
|
— |
|
|
— |
|
* |
|
4.2 |
|
|
— |
|
|
4.2 |
|
|
* |
||||||||
Stock-based compensation |
|
|
0.1 |
|
|
— |
|
|
0.1 |
|
* |
|
0.3 |
|
|
— |
|
|
0.3 |
|
|
* |
||||||||
Environmental remediation costs |
|
|
— |
|
|
0.3 |
|
|
(0.3 |
) |
* |
|
— |
|
|
6.9 |
|
|
(6.9 |
) |
|
* |
||||||||
Foreign currency losses (gains), net |
|
|
2.4 |
|
|
(0.4 |
) |
|
2.8 |
|
* |
|
16.6 |
|
|
4.6 |
|
|
12.0 |
|
|
* |
||||||||
Adjusted EBITDA |
|
$ |
29.7 |
|
$ |
27.4 |
|
$ |
2.3 |
|
9 |
% |
$ |
77.8 |
|
$ |
80.4 |
|
$ |
(2.6 |
) |
|
(3 |
)% |
Amounts and percentages may reflect rounding adjustments. | ||
* |
Calculation not meaningful |
|
(1) |
Reflects ratio to total net sales |
Phibro Animal Health Corporation |
||||||||||||||||||||||||||||||
Adjusted Net Income |
||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
|
|
Three Months |
|
Nine Months |
||||||||||||||||||||||||||
For the Periods Ended March 31 |
|
2024 |
|
2023 |
|
Change |
|
2024 |
|
2023 |
|
Change |
||||||||||||||||||
|
|
(in millions, except per share amounts and percentages) |
||||||||||||||||||||||||||||
Reconciliation of GAAP Net Income to Adjusted Net Income |
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||
Net income |
|
$ |
8.4 |
|
$ |
10.0 |
|
$ |
(1.6 |
) |
|
(16 |
)% |
$ |
1.7 |
|
$ |
21.1 |
|
$ |
(19.4 |
) |
* |
|||||||
Acquisition-related intangible amortization (1) |
|
|
1.7 |
|
|
1.7 |
|
|
0.0 |
|
|
1 |
% |
|
5.0 |
|
|
5.0 |
|
|
0.0 |
|
1 |
% |
||||||
Acquisition-related intangible amortization (2) |
|
|
0.8 |
|
|
0.8 |
|
|
(0.0 |
) |
|
(1 |
)% |
|
2.3 |
|
|
2.3 |
|
|
0.0 |
|
2 |
% |
||||||
Acquisition-related cost of goods sold (1) |
|
|
0.2 |
|
|
— |
|
|
0.2 |
|
|
* |
|
0.5 |
|
|
— |
|
|
0.5 |
|
* |
||||||||
Acquisition-related other (2) |
|
|
0.5 |
|
|
— |
|
|
0.5 |
|
|
* |
|
0.5 |
|
|
— |
|
|
0.5 |
|
* |
||||||||
Pension settlement cost (2) |
|
|
— |
|
|
— |
|
|
— |
|
|
* |
|
10.7 |
|
|
— |
|
|
10.7 |
|
* |
||||||||
|
|
|
— |
|
|
— |
|
|
— |
|
|
* |
|
4.2 |
|
|
— |
|
|
4.2 |
|
* |
||||||||
Insurance proceeds (2) |
|
|
(0.3 |
) |
|
— |
|
|
(0.3 |
) |
|
* |
|
(0.3 |
) |
|
— |
|
|
(0.3 |
) |
* |
||||||||
Stock-based compensation (2) |
|
|
0.1 |
|
|
— |
|
|
0.1 |
|
|
* |
|
0.3 |
|
|
— |
|
|
0.3 |
|
* |
||||||||
Environmental remediation costs (2) |
|
|
— |
|
|
0.3 |
|
|
(0.3 |
) |
|
* |
|
— |
|
|
6.9 |
|
|
(6.9 |
) |
* |
||||||||
Foreign currency losses (gains), net (3) |
|
|
2.4 |
|
|
(0.4 |
) |
|
2.8 |
|
|
* |
|
16.6 |
|
|
4.6 |
|
|
12.0 |
|
* |
||||||||
Adjustments to income taxes (4) |
|
|
(1.1 |
) |
|
(0.7 |
) |
|
(0.4 |
) |
|
* |
|
(9.8 |
) |
|
(6.1 |
) |
|
(3.7 |
) |
* |
||||||||
Adjusted net income |
|
$ |
12.7 |
|
$ |
11.6 |
|
$ |
1.1 |
|
|
9 |
% |
$ |
31.7 |
|
$ |
33.8 |
|
$ |
(2.1 |
) |
(6 |
)% |
||||||
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||
Statement of Operations Line Items - adjusted |
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||
Adjusted cost of goods sold (1) |
|
$ |
181.7 |
|
$ |
168.5 |
|
$ |
13.3 |
|
|
8 |
% |
$ |
513.0 |
|
$ |
496.3 |
|
$ |
16.7 |
|
3 |
% |
||||||
Adjusted gross profit |
|
|
81.5 |
|
|
77.2 |
|
|
4.3 |
|
|
6 |
% |
|
231.5 |
|
|
226.5 |
|
|
4.9 |
|
2 |
% |
||||||
Adjusted selling, general and administrative (2) |
|
|
58.5 |
|
|
55.9 |
|
|
2.6 |
|
|
5 |
% |
|
173.3 |
|
|
164.3 |
|
|
9.0 |
|
5 |
% |
||||||
Adjusted interest expense, net |
|
|
4.6 |
|
|
3.9 |
|
|
0.7 |
|
|
18 |
% |
|
13.8 |
|
|
10.8 |
|
|
3.0 |
|
28 |
% |
||||||
Adjusted income before income taxes |
|
|
18.4 |
|
|
17.4 |
|
|
0.9 |
|
|
5 |
% |
|
44.4 |
|
|
51.4 |
|
|
(7.0 |
) |
(14 |
)% |
||||||
Adjusted provision for income taxes (4) |
|
|
5.7 |
|
|
5.8 |
|
|
(0.1 |
) |
|
(2 |
)% |
|
12.7 |
|
|
17.7 |
|
|
(5.0 |
) |
(28 |
)% |
||||||
Adjusted net income |
|
$ |
12.7 |
|
$ |
11.6 |
|
$ |
1.1 |
|
|
9 |
% |
$ |
31.7 |
|
$ |
33.8 |
|
$ |
(2.1 |
) |
(6 |
)% |
||||||
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||
Adjusted net income per share |
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||
diluted |
|
$ |
0.31 |
|
$ |
0.29 |
|
$ |
0.02 |
|
|
9 |
% |
$ |
0.78 |
|
$ |
0.83 |
|
$ |
(0.05 |
) |
(6 |
)% |
||||||
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||
Weighted average common shares outstanding |
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||
diluted |
|
|
40.5 |
|
|
40.5 |
|
|
|
|
|
40.5 |
|
|
40.5 |
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||
Ratio to net sales |
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||
Adjusted gross profit |
|
|
31.0 |
% |
|
31.4 |
% |
|
|
|
|
31.1 |
% |
|
31.3 |
% |
|
|
||||||||||||
Adjusted selling, general and administrative |
|
|
22.2 |
% |
|
22.8 |
% |
|
|
|
|
23.3 |
% |
|
22.7 |
% |
|
|
||||||||||||
Adjusted income before income taxes |
|
|
7.0 |
% |
|
7.1 |
% |
|
|
|
|
6.0 |
% |
|
7.1 |
% |
|
|
||||||||||||
Adjusted net income |
|
|
4.8 |
% |
|
4.7 |
% |
|
|
|
|
4.3 |
% |
|
4.7 |
% |
|
|
||||||||||||
Adjusted effective tax rate |
|
|
30.8 |
% |
|
33.2 |
% |
|
|
|
|
28.6 |
% |
|
34.3 |
% |
|
|
Amounts and percentages may reflect rounding adjustments. | ||
* |
Calculation not meaningful | |
(1) |
Adjusted cost of goods sold excludes acquisition-related intangible amortization and acquisition-related cost of goods sold |
|
(2) |
Adjusted selling, general and administrative excludes acquisition-related intangible amortization, pension settlement cost, |
|
(3) |
Foreign currency losses (gains), net, are excluded from adjusted net income |
|
(4) |
Adjusted provision for income taxes excludes the income tax effect of pre-tax income adjustments and certain income tax items |
Phibro Animal Health Corporation |
||||||||||||||||||||||||
Operating, Investing and Free Cash Flows |
||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
Three Months |
|
Nine Months |
||||||||||||||||||||
For the Periods Ended March 31 |
|
2024 |
|
2023 |
|
Change |
|
2024 |
|
2023 |
|
Change |
||||||||||||
|
|
(in millions) |
||||||||||||||||||||||
EBITDA |
|
$ |
26.7 |
|
|
$ |
27.5 |
|
|
$ |
(0.8 |
) |
|
$ |
45.3 |
|
|
$ |
68.9 |
|
|
$ |
(23.6 |
) |
Adjustments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Acquisition-related cost of goods sold |
|
|
0.2 |
|
|
|
— |
|
|
|
0.2 |
|
|
|
0.5 |
|
|
|
— |
|
|
|
0.5 |
|
Acquisition-related other |
|
|
0.5 |
|
|
|
— |
|
|
|
0.5 |
|
|
|
0.5 |
|
|
|
— |
|
|
|
0.5 |
|
Pension settlement cost |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
10.7 |
|
|
|
— |
|
|
|
10.7 |
|
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
4.2 |
|
|
|
— |
|
|
|
4.2 |
|
Insurance proceeds |
|
|
(0.3 |
) |
|
|
— |
|
|
|
(0.3 |
) |
|
|
(0.3 |
) |
|
|
— |
|
|
|
(0.3 |
) |
Stock-based compensation |
|
|
0.1 |
|
|
|
— |
|
|
|
0.1 |
|
|
|
0.3 |
|
|
|
— |
|
|
|
0.3 |
|
Environmental remediation costs |
|
|
— |
|
|
|
0.3 |
|
|
|
(0.3 |
) |
|
|
— |
|
|
|
6.9 |
|
|
|
(6.9 |
) |
Foreign currency losses (gains), net |
|
|
2.4 |
|
|
|
(0.4 |
) |
|
|
2.8 |
|
|
|
16.6 |
|
|
|
4.6 |
|
|
|
12.0 |
|
Interest paid, net |
|
|
(4.3 |
) |
|
|
(3.7 |
) |
|
|
(0.6 |
) |
|
|
(13.0 |
) |
|
|
(10.3 |
) |
|
|
(2.7 |
) |
Income taxes paid |
|
|
(2.5 |
) |
|
|
(6.8 |
) |
|
|
4.4 |
|
|
|
(11.6 |
) |
|
|
(16.2 |
) |
|
|
4.6 |
|
Changes in operating assets and liabilities and other items |
|
|
(11.5 |
) |
|
|
(10.6 |
) |
|
|
(1.0 |
) |
|
|
5.9 |
|
|
|
(60.9 |
) |
|
|
66.8 |
|
Net cash provided (used) by operating activities |
|
$ |
11.4 |
|
|
$ |
6.3 |
|
|
$ |
5.1 |
|
|
$ |
59.2 |
|
|
$ |
(6.9 |
) |
|
$ |
66.1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Short-term investments, net |
|
$ |
11.0 |
|
|
$ |
(30.0 |
) |
|
$ |
41.0 |
|
|
$ |
(8.5 |
) |
|
$ |
(23.0 |
) |
|
$ |
14.5 |
|
Capital expenditures |
|
|
(9.7 |
) |
|
|
(7.9 |
) |
|
|
(1.8 |
) |
|
|
(28.2 |
) |
|
|
(40.9 |
) |
|
|
12.7 |
|
Business acquisition |
|
|
0.0 |
|
|
|
— |
|
|
|
0.0 |
|
|
|
(3.3 |
) |
|
|
— |
|
|
|
(3.3 |
) |
Other investing, net |
|
|
(0.2 |
) |
|
|
0.1 |
|
|
|
(0.3 |
) |
|
|
0.9 |
|
|
|
0.2 |
|
|
|
0.7 |
|
Net cash provided (used) by investing activities |
|
$ |
1.1 |
|
|
$ |
(37.8 |
) |
|
$ |
38.9 |
|
|
$ |
(39.1 |
) |
|
$ |
(63.7 |
) |
|
$ |
24.7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Free cash flow: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Net cash provided (used) by operating activities |
|
$ |
11.4 |
|
|
$ |
6.3 |
|
|
$ |
5.1 |
|
|
$ |
59.2 |
|
|
$ |
(6.9 |
) |
|
$ |
66.1 |
|
Capital expenditures |
|
|
(9.7 |
) |
|
|
(7.9 |
) |
|
|
(1.8 |
) |
|
|
(28.2 |
) |
|
|
(40.9 |
) |
|
|
12.7 |
|
Building purchase (1) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
15.0 |
|
|
|
(15.0 |
) |
Free cash flow (adjusted) |
|
$ |
1.7 |
|
|
$ |
(1.6 |
) |
|
$ |
3.3 |
|
|
$ |
31.0 |
|
|
$ |
(32.8 |
) |
|
$ |
63.8 |
|
Amounts and percentages may reflect rounding adjustments. | ||
|
||
(1) |
Adjusted free cash flow for the nine months ended March 31, 2023, excludes a |
About Phibro Animal Health Corporation
Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians, and consumers who raise or care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. For further information, please visit www.pahc.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240508241426/en/
Phibro Animal Health Corporation
Glenn C. David
Chief Financial Officer
+1-201-329-7300
Or
investor.relations@pahc.com
Source: Phibro Animal Health Corporation
FAQ
What were Phibro's net sales for the third quarter of 2024?
What was the adjusted EBITDA for Phibro in the third quarter of 2024?
What is Phibro's fiscal year 2024 guidance for net sales?
How did Phibro's adjusted diluted EPS perform in the third quarter of 2024?